• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    12/2/25 8:27:24 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care
    Get the next $UFPT alert in real time by email
    ufpt-20251201
    FALSE000091415600009141562025-12-012025-12-01

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    _________________
    FORM 8-K
    _________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): December 1, 2025
    _______________________________
    UFP TECHNOLOGIES, INC.
    (Exact name of registrant as specified in its charter)
    _______________________________
    Delaware001-1264804-2314970
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
    100 Hale Street
    Newburyport, Massachusetts - USA 01950-3504
    (Address of Principal Executive Offices) (Zip Code)
    (978) 352-2200
    (Registrant's telephone number, including area code)
    N/A
    (Former name or former address, if changed since last report)
    _______________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common StockUFPT
    The NASDAQ Stock Market L.L.C.
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 5.02             Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    Departure of Chief Executive Officer

    On December 1, 2025, R. Jeffrey Bailly, Chief Executive Officer of UFP Technologies, Inc., a Delaware corporation (the “Company”), announced his retirement from his position as Chief Executive Officer of the Company, effective as of the completion of the Company’s Annual Meeting of Stockholders currently scheduled for June 4, 2026 (the “Effective Date”). Mr. Bailly’s retirement was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including accounting principles and practices. Mr. Bailly intends to remain on the Board of Directors of the Company (the “Board”).

    Appointment of Chief Executive Officer

    Subject to Mitchell C. Rock’s execution and delivery of an Employment Offer Letter, in form and substance satisfactory to the Company, Mr. Rock will serve as the Chief Executive Officer of the Company, effective as of the Effective Date.

    Mr. Rock, age 58, initially joined the Company in 1991 and served as Director, Sales and Marketing of what was the Company’s Moulded Fibre division. From May 1999 through October 2000, Mr. Rock left the Company to serve as Vice President, Sales and Business Development of Esprocket, an internet start-up company. Mr. Rock rejoined the Company in April 2001 as Vice President, Sales and Marketing of the Moulded Fibre division and served as the Company’s Vice President of Sales and Marketing from May 2002 to June 2014. From June 2014 to June 2021, Mr. Rock served as the Company’s Senior Vice President of Sales and Marketing, and from January 1, 2020 to June 2021, Mr. Rock also served as General Manager, Medical. From June 2021, Mr. Rock served as President, UFP MedTech. Since February 2024, Mr. Rock has served as President of the Company. Since 2016, Mr. Rock has also served on the board of directors of Outlook Amusements, Inc., an entertainment company specializing in advice-based products and services.

    Other than the Employment Offer Letter, there are no arrangements or understandings between Mr. Rock and any other person pursuant to which Mr. Rock will be promoted to Chief Executive Officer of the Company. There are no family relationships between Mr. Rock and any director or executive officer of the Company, and he has no indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. For more information about Mr. Rock, please see the Company’s definitive proxy statement on DEF 14A, filed with the U.S. Securities and Exchange Commission on April 30, 2025.

    Appointment of Executive Chairman of the Board

    Additionally, on December 1, 2025, the Board appointed Mr. Bailly as Executive Chairman of the Board, effective as of the Effective Date. For more information about Mr. Bailly, please see the Company’s definitive proxy statement on DEF 14A, filed with the U.S. Securities and Exchange Commission on April 30, 2025.

    Item 7.01             Regulation FD Disclosure.
    On December 1, 2025, the Company issued a press release announcing the retirement of Mr. Bailly and the appointment of Mr. Rock as its Chief Executive Officer, a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1.

    Limitation on Incorporation by Reference. The information furnished in this Item 7.01, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

    Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements.
    Item 9.01. Financial Statements and Exhibits.
    (d) Exhibits



    Exhibit NumberDescription
    99.1
    Press Release dated December 1, 2025
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    UFP Technologies, Inc.
    Date: December 1, 2025By: /s/ Ronald J. Lataille        
    Ronald J. Lataille
    Chief Financial Officer and Senior Vice President

    Get the next $UFPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UFPT

    DatePrice TargetRatingAnalyst
    3/28/2025Mkt Perform
    Raymond James
    7/17/2024$344.00 → $392.00Buy
    Lake Street
    3/20/2024Market Outperform
    CJS Securities
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    12/21/2022$124.00Buy
    Lake Street
    6/22/2022$110.00Buy
    Lake Street
    11/19/2021$81.00Buy
    Colliers Securities
    More analyst ratings

    $UFPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior Vice President Litterio Christopher P. sold $415,550 worth of shares (1,829 units at $227.20), decreasing direct ownership by 15% to 10,756 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    11/12/25 11:23:21 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Director Croteau Daniel C sold $591,883 worth of shares (2,873 units at $206.02), decreasing direct ownership by 77% to 855 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    9/8/25 2:55:37 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Director Croteau Daniel C exercised 1,318 shares at a strike of $22.36, increasing direct ownership by 55% to 3,728 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    8/14/25 5:40:39 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    UFP Technologies Announces CEO Succession Plan

    NEWBURYPORT, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that R. Jeffrey Bailly will retire as CEO at the Company's next annual meeting on June 4, 2026. At that time, Mitchell Rock, President of the Company, will assume the CEO position and join the Company's Board. To facilitate a smooth transition, Mr. Bailly will serve as Executive Chairman of the Board for the following year. "Serving as CEO for 31 years, Jeff has been an extremely effective leader who, together with his team, transitioned the company to a leading g

    12/2/25 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies to Present and Host 1X1 Investor Meetings at the Piper Sandler 37th Annual Healthcare Conference

    NEWBURYPORT, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT) a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that Chairman and Chief Executive Officer R. Jeffrey Bailly, President Mitchell C. Rock, and Chief Financial Officer Ron Lataille will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference to be held in New York City December 1-4, 2025. UFP's presentation is scheduled to begin at 8:10 AM on Wednesday, December 3rd. A live audio webcast of UFP's presentation will be available here. About UFP Technologies, Inc.UFP Technologies is a contract deve

    11/25/25 4:10:00 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Announces Strong Q3 2025 Results

    NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per dilute

    11/3/25 4:08:33 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    SEC Filings

    View All

    UFP Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)

    12/2/25 8:31:01 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - UFP TECHNOLOGIES INC (0000914156) (Filer)

    12/2/25 8:27:24 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by UFP Technologies Inc.

    10-Q - UFP TECHNOLOGIES INC (0000914156) (Filer)

    11/7/25 7:55:24 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on UFP Technologies

    Raymond James initiated coverage of UFP Technologies with a rating of Mkt Perform

    3/28/25 8:21:18 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Lake Street reiterated coverage on UFP Technologies with a new price target

    Lake Street reiterated coverage of UFP Technologies with a rating of Buy and set a new price target of $392.00 from $344.00 previously

    7/17/24 8:57:19 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    CJS Securities initiated coverage on UFP Technologies

    CJS Securities initiated coverage of UFP Technologies with a rating of Market Outperform

    3/20/24 9:43:53 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Lataille Ronald J bought $91,636 worth of shares (400 units at $229.09), increasing direct ownership by 3% to 15,031 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    2/27/25 3:57:17 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Lataille Ronald J

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    11/13/23 11:09:49 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Rock Mitchell bought $27,522 worth of shares (198 units at $139.00), increasing direct ownership by 0.74% to 27,086 units (SEC Form 4)

    4 - UFP TECHNOLOGIES INC (0000914156) (Issuer)

    11/9/23 5:21:17 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Leadership Updates

    Live Leadership Updates

    View All

    UFP Technologies Acquires AQF Medical

    NEWBURYPORT, Mass., Aug. 26, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of AQF Limited ("AQF Medical"). Headquartered in Navan, Ireland with additional joint venture operations in Singapore, AQF Medical develops and manufactures custom-engineered foam and thermoplastic components used in a wide range of medical devices and packaging. "We are excited about the addition of AQF Medical, our fourth acquisition in the past few months," said R. Jeffrey Bailly, Chairman and CEO of UFP Technologies.

    8/26/24 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Acquires Marble Medical

    NEWBURYPORT, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products, today announced the acquisition of Marble Medical. Founded in 1988 and headquartered in Tallahassee, FL, Marble Medical develops and manufactures adhesive based medical components and single-use devices. "Adding Marble Medical's adhesives expertise is a great complement to our surgical robot drapes and stick to skin device platforms," said R. Jeffrey Bailly, chairman and CEO of UFP Technologies. "Marble Medical is a 3M Preferred Converter, and along wi

    7/16/24 4:05:00 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    Chimerix Appoints Marc D. Kozin to Board of Directors

    DURHAM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Marc D. Kozin as the newest member of the Company's Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company's 2024 Annual Meeting of Stockholders in June, after ten years of service. "We are pleased to welcome Marc to the Board of Directors. Marc's strategic insights and leadership will undoubtedly contribute to the continued growth and success of Chimerix as we wo

    3/21/24 7:00:00 AM ET
    $CMRX
    $UFPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $UFPT
    Financials

    Live finance-specific insights

    View All

    UFP Technologies Announces Strong Q3 2025 Results

    NEWBURYPORT, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $16.4 million or $2.11 per diluted common share outstanding for its third quarter ended September 30, 2025, the same as in Q3 of 2024. Adjusted earnings per diluted share outstanding for the third quarter ended September 30, 2025, was $2.39. Sales for the third quarter were $154.6 million compared to sales of $145.2 million in the third quarter of 2024. Net income for the nine-month period ended September 30, 2025, was $50.7 million or $6.52 per dilute

    11/3/25 4:08:33 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies to Report Third Quarter 2025 Financial Results on November 3, 2025

    NEWBURYPORT, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today announced that the Company plans to report results for the third quarter on Monday, November 3rd, after the close of the stock market. The Company will hold a conference call to discuss the results on the following day, November 4th, at 8:30 AM Eastern time. Conference Call Information:Date: Tuesday, November 4, 2025Time: 8:30 AM Eastern Time Participants may join the call using the following dial-in numbers: USA/Canada: Toll-Free: 1-412-206-6478International: 1-833-890-4

    10/29/25 9:00:00 AM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    UFP Technologies Announces Record Q2 Results

    NEWBURYPORT, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (NASDAQ:UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported net income of $17.2 million or $2.21 per diluted common share outstanding for its second quarter ended June 30, 2025, compared to net income of $13.6 million or $1.75 per diluted common share outstanding for the same quarter in 2024. Adjusted earnings per diluted common share outstanding grew 27% to $2.50. Sales for the second quarter were $151.2 million compared to sales of $110.2 million in the second quarter of 2024. Net income for the six-month period ended June

    8/4/25 4:15:31 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    $UFPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by UFP Technologies Inc.

    SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

    11/13/24 9:58:23 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by UFP Technologies Inc. (Amendment)

    SC 13G/A - UFP TECHNOLOGIES INC (0000914156) (Subject)

    3/8/24 3:02:25 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by UFP Technologies Inc.

    SC 13G - UFP TECHNOLOGIES INC (0000914156) (Subject)

    2/13/24 5:16:09 PM ET
    $UFPT
    Medical/Dental Instruments
    Health Care